Literature DB >> 11240708

Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer.

H. S. Ryu1, K. H. Chang, S. J. Chang, M. S. Kim, H. J. Joo, K. S. Oh.   

Abstract

Apoptosis is an intrinsic and fundamental biologic process that plays a critical role in the normal development of multicellular organisms and in the maintainance of tissue homeostasis. Some of the well known regulators of apoptosis are cytokines of the tumor necrosis factor (TNF) ligand family, such as Fas ligand (Fas L) and TNF, which induce apoptosis by activation of their corresponding receptors, Fas and TNFR-1. Recently, a new member of the TNF family known as TRAIL (TNF-related apoptosis-inducing ligand) was identified and shown to induce p53-independent apoptosis in a variety of tumor cell lines but not in normal cells. Four human receptors for TRAIL were also recently identified and designated TRAIL-R1, -R2, -R3, and -R4. The aim of this study is to examine whether TRAIL and TRAIL receptors (-R1, -R2, -R3) are expressed in uterine cervical cancer and whether it is correlated with apoptosis, TRAIL, and TRAIL receptors. The subjects were 20 patients who were diagnosed with cervical cancer. Western blotting was performed in nine cases and immunohistochemical staining for TRAIL and TRAIL receptors (-R1, -R2, -R3) and TUNEL method for detection of apoptosis was performed in 11 cases. There were proteins for TRAIL, TRAIL-R1, -R2, and -R3 in tissues from cervical cancer. All TRAIL receptors were expressed in both normal cervical epithelium and tumor cells, and TRAIL-R1 and -R2 were more strongly expressed in tumor cells than normal epithelium (P < 0.05). Apoptosis correlated with expression of TRAIL-R1 and -R2 (P < 0.05). This study suggests that TRAIL induces apoptosis in cervical cancer through its receptors.

Entities:  

Year:  2000        PMID: 11240708     DOI: 10.1046/j.1525-1438.2000.010005417.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.

Authors:  Elenia Riddick; Shavonda Evans; Jeffrey Rousch; Ephraim Gwebu; Hirendra Nath Banerjee
Journal:  J Solid Tumors       Date:  2013-12-01

2.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

4.  Apoptosis and expression of protein TRAIL in granulosa cells of rats with polycystic ovarian syndrome.

Authors:  Juan Zhang; Guijin Zhu; Xinrong Wang; Bei Xu; Linli Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-06

5.  Comprehensive Molecular Analyses of a TNF Family-Based Gene Signature as a Potentially Novel Prognostic Biomarker for Cervical Cancer.

Authors:  Yan Ma; Xiaoyan Zhang; Jiancheng Yang; Yanping Jin; Ying Xu; Jianping Qiu
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

6.  Fermented Mangosteen (Garcinia mangostana L.) Supplementation in the Prevention of HPV-Induced Cervical Cancer: From Mechanisms to Clinical Outcomes.

Authors:  Zaira Kharaeva; Pavel Trakhtman; Ilya Trakhtman; Chiara De Luca; Wolfgang Mayer; Jessie Chung; Galina Ibragimova; Liudmila Korkina
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

7.  Human and simian immunodeficiency virus-mediated upregulation of the apoptotic factor TRAIL occurs in antigen-presenting cells from AIDS-susceptible but not from AIDS-resistant species.

Authors:  Nayoung Kim; Alicja Dabrowska; Richard G Jenner; Anna Aldovini
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.